Anidulafungin is manufactured by Pfizer.
This potent medication, also known by its brand name Eraxis, is an anti-fungal drug vital in treating various fungal infections.
Key Details About Anidulafungin
Anidulafungin has a significant history and specific characteristics that define its role in medical treatment. Here's a brief overview:
- Manufacturer: The pharmaceutical giant Pfizer is responsible for the production of Anidulafungin.
- Drug Type: It belongs to the class of anti-fungal medications, specifically echinocandins, which work by inhibiting the synthesis of a key component of the fungal cell wall.
- Alternative Name: While its generic name is Anidulafungin, it is also widely recognized by its brand name, Eraxis.
- FDA Approval: Anidulafungin received approval from the U.S. Food and Drug Administration (FDA) on February 21, 2006, marking its official entry into the market for clinical use.
- Previous Designation: Prior to its approval and widely known names, the drug was referred to as LY303366 during its development phase.
For a quick reference, here's a summary of its core information:
| Feature | Detail |
|---|---|
| Manufacturer | Pfizer |
| Brand Name | Eraxis |
| Drug Type | Anti-fungal |
| FDA Approval Date | February 21, 2006 |
| Previous Designation | LY303366 |
Anidulafungin's journey from a developmental compound to an FDA-approved drug manufactured by Pfizer highlights its importance in the arsenal against fungal pathogens. For more detailed information on Anidulafungin, including its uses, interactions, and mechanism of action, you can refer to reputable sources like DrugBank.
